| 2026-08-11 | Press release | Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update |
| 2026-07-15 | Press release | Cardiff Oncology Announces $10 Million Registered Direct Offering |
| 2026-06-02 | Press release | Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib |
| 2026-06-01 | Press release | Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference |
| 2026-05-21 | Press release | Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mC |
| 2026-05-14 | Press release | Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update |
| 2026-04-28 | Press release | Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-27 | Press release | Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity |
| 2026-04-21 | Press release | Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session a |
| 2026-04-17 | Press release | Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at |
| 2026-04-09 | Press release | Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth |
| 2026-03-20 | Press release | Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer |
| 2026-03-19 | Press release | Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Mee |
| 2026-02-26 | Press release | Cardiff Oncology to Participate in Three Upcoming Investor Conferences |
| 2026-02-24 | Press release | Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update |
| 2026-02-19 | Press release | Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-01-27 | Press release | Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mC |
| 2025-12-08 | Press release | Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference |
| 2025-12-08 | Press release | Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Le |
| 2025-11-24 | Press release | Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 2025-11-04 | Press release | Cardiff Oncology to Participate in Two Upcoming Investor Conferences |
| 2025-10-02 | Press release | Cardiff Oncology to Participate in Two Upcoming Investor Conferences |
| 2025-08-28 | Press release | Cardiff Oncology to Participate in Three Upcoming Investor Conferences |
| 2025-07-29 | Press release | Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRD |
| 2025-06-02 | Press release | Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel |
| 2025-04-15 | Press release | Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment o |
| 2025-02-24 | Press release | Cardiff Oncology to Present at Upcoming Investor Conferences |
| 2024-12-10 | Press release | Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial |
| 2024-10-30 | Press release | Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutan |
| 2024-05-29 | Press release | Cardiff Oncology to Present at the Jefferies Healthcare Conference |
| 2024-05-13 | Press release | Cardiff Oncology to Present at Upcoming Investor Conferences in May |
| 2024-02-29 | Press release | Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated |
| 2024-02-29 | Press release | Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial ( |
| 2024-02-29 | Press release | Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update |
| 2024-02-26 | Press release | Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference |
| 2024-02-22 | Press release | Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update |
| 2024-01-17 | Press release | Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer R |
| 2023-11-20 | Press release | Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference |
| 2023-09-26 | Press release | Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agen |
| 2023-09-05 | Press release | Cardiff Oncology to Present at Upcoming Investor Conferences in September |